Furthermore, lycopene exerted promising in vitro activity against prostatic carcinoma cells (LNCaP) by eliciting Ras inactivation, reducing the activation of NF-κB, decreasing the level of ROS, inhibiting the phosphorylation of c-jun N-terminal kinase, extracellular signal-regulated kinase 1/2, and p38. Here, MAPK3 is linked to prostate carcinoma.